Immunotherapy for non-metastatic colon cancer before surgery
Part of Cancer, Digestive system clinical trials.
This trial tests two immunotherapy drugs (cemiplimab and fianlimab) before surgery for colon cancer that hasn't spread. It's for people with a specific tumor type (pMMR/MSS) who are candidates for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III or T4 colon cancer that has not spread to other organs.
- Your tumor is 'pMMR' or 'MSS' (a type that doesn't have certain DNA repair issues).
- You are healthy enough for surgery to remove the cancer.
- You have not had prior immunotherapy or other cancer treatments for this cancer.
- You do not have autoimmune diseases, active infections, or other serious health issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This trial tests if the immunotherapy drug pembrolizumab can shrink colon cancers with specific genetic features (dMMR/MSI-H) before surgery. If the tumor responds well, some patients might avoid chemotherapy after surgery. It is for people with newly diagnosed, localized colon or upper rectal cancer.
This trial tests whether adding a new immunotherapy drug (ivonescimab) to standard chemotherapy (CAPOX) before surgery can improve outcomes for people with locally advanced colon cancer. It compares the combination to chemotherapy alone.
This trial tests two immunotherapy drugs, zanzalintinib and retifanlimab, given before surgery to remove colon cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes for people with a specific type of colon cancer (called pMMR/MSS).
This Phase 2 trial tests immune “checkpoint” medicines (and combinations) given before colon surgery to see if they can better control early colon cancer. It is aimed at people with non-metastatic colon cancer and certain tumor markers.
This trial tests whether two immunotherapy drugs (cemiplimab and fianlimab) given before surgery can help treat stage IB to IIIB non-small cell lung cancer. You must have a PD-L1 level of at least 1% and your surgeon must think the tumor can be fully removed.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.